Business
Oncolytics Biotech® Inc. Announces Details of 2016 Annual Meeting of Shareholders
Oncolytics Biotech® Inc. Announces Details of 2016 Annual Meeting of Shareholders ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Announces Details of 2016 Annual Meeting of Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncolytics Biotech® Inc. Announces Details of 2016 Annual Meeting of Shareholders\nCanada NewsWire\nCALGARY, May 3, 2016\n\n\n\nCALGARY, May 3, 2016 /CNW/ - Oncolytics Biotech® Inc. (\"Oncolytics\" or the \"Company\") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) announced today that its 2016 Annual Meeting of Shareholders will be held on Thursday, May 5th, 2016 at 4:00 pm ET (2:00 pm MT) at the Toronto Region Board of Trade located at First Canadian Place, Suite 350, 77 Adelaide St. West, Toronto, Ontario.\n\nFollowing the business portion of the meeting, Dr. Brad Thompson, President and CEO of Oncolytics, will discuss recent progress in the development of REOLYSIN® as a potential cancer therapeutic. \n\nA live audio webcast of Dr. Thompson's presentation will begin at approximately 4:15 pm ET (2:15 pm MT) and be available at: http://event.on24.com/r.htm?e=1162870&s=1&k=8D8411394AC01E5C5A9CDC57BFA2ED10 or on the company's website at www.oncolyticsbiotech.com. It is recommended that listeners log on 10 minutes in advance of the presentation to register and download any necessary software. \n\nAn audio replay will be accessible following the presentation at: http://www.oncolyticsbiotech.com/investor-centre/presentations/. \n\nAbout Oncolytics Biotech Inc.Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.\n\nThis press release and the presentation related thereto contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYS...